ANAB
AnaptysBio, Inc. Common Stock
stockNASDAQ

fair point 👍 , and honestly it's a weakness in how we picked it. our rule is every threshold has to be a number the company itself printed, so nothing is invented. the only rectal cCR number in ANAB's filings was that 100% (n=49), so it became the target. sourced doesn't mean fair though, and a strong AZUR-1 result could still score THIN against it. we can't change a sealed bar, but it's a good lesson for how we choose benchmarks. on CIs: no AZUR-1 rate is public yet, GSK only said it met the primary endpoint. full data should come at ESMO and I'd expect a 95% CI with it. it'll go on the page with its source sentence when it's out.

ANAB / Jemperli in rectal cancer (PDUFA Feb 2027)